MiniMed Flex (formerly NMX8-AID)
MiniMed
MiniMed's FDA-cleared, screenless, smartphone-controlled successor to the 780G pump line. Flex uses SmartGuard advanced hybrid closed-loop automation, Simplera Sync CGM, a 300-unit reservoir, 7-day rechargeable battery and app bolusing. The GATEWAY registry still tracks it under the NMX8-AID name and includes flexible/no-meal-bolus arms, but public Flex performance data are not yet as mature as 780G real-world data.
The scorecard
Uses MiniMed SmartGuard automation, whose predecessor 780G has strong real-world evidence, but Flex-specific GATEWAY outcomes are not posted yet; scored below mature 780G until direct data report.[1]
SmartGuard includes predictive low suspend and automated basal/correction behavior, and GATEWAY directly measures time below 70 mg/dL, but Flex-specific safety outcomes are still pending.[3]
Product release is an advanced hybrid loop with app bolusing; the GATEWAY protocol explicitly tests no-meal-bolus and flexible meal-bolus modes, making this a real step toward lower-burden meal automation.[3]
Smaller, screenless, smartphone-controlled pump with app meal/correction boluses and a 7-day battery is freer than a classic pump body, but it remains tubed.[1]
Expected to inherit SmartGuard glucose performance, but no Flex-specific mean glucose, GMI, or HbA1c results have been posted.[1]
SmartGuard should reduce excursions through automated correction and basal changes, but GATEWAY variability results are still unavailable.[3]
The trial collects exercise logs and SmartGuard includes low protection, but no Flex-specific exercise-mode results are public.[3]
The system supports app control, SmartGuard settings, and GATEWAY meal modes, but it remains a closed MiniMed ecosystem rather than a deeply tunable algorithm.[1]
FDA-cleared in the US for T1D ages 7+ and insulin-requiring T2D adults, with select-customer spring 2026 launch and broad US launch planned for summer; pricing and ex-US rollout are still unclear.[2]
Glycemic criteria are scored on the levels actually achieved in large real-world Type 1 diabetes cohorts — not the headline improvement over a trial's baseline (an improvement that looks bigger when the starting population was doing poorly). Type 2 diabetes trial data is never used to score a Type 1 system; where only improvement data exists, it informs the rationale, not the score. Freedom captures form factor and wearability, so a tubeless system is rewarded for the mobility a tubed one can't match.
The full picture
MiniMed Flex is the public product name for the next-generation system that the GATEWAY registry still calls NMX8-AID. It is now FDA-cleared in the United States: a small screenless pump controlled through the MiniMed app, paired with SmartGuard automation, Simplera Sync CGM, standard MiniMed infusion sets, a 300-unit reservoir and a rechargeable battery lasting at least seven days.
The reason it stays in the "frontier" set is the GATEWAY protocol. Beyond standard hybrid-loop use, GATEWAY tests flexible meal-bolus behavior, including a no-meal-bolus arm. That is a direct move toward lower-burden meal automation. The caveat is evidence maturity: the pump is cleared, but public Flex-specific time-in-range, hypoglycemia and no-meal-bolus outcomes are not posted yet. Until those arrive, Flex should be treated as an approved hardware/control upgrade with promising automation direction, not as proven fully closed loop.
What's next for this
- →Broader US commercial launch · summer 2026
- →GATEWAY safety study completion and meal-mode data · primary completion estimated January 2027
Sources
- [1]MiniMed Flex system product FAQ · manufacturer
- [2]MiniMed announces FDA clearance of MiniMed Flex, its smallest insulin pump and first smartphone-controlled design · manufacturer · 2026-03-18
- [3]GATEWAY Safety Evaluation of the MiniMed NMX8-AID System in Children and Adults Living With Diabetes · registry · 2026-06-08